Basit öğe kaydını göster

dc.contributor.authorKaradogan, Dilek
dc.contributor.authorOnal, Ozgur
dc.contributor.authorSahin, Deniz Say
dc.contributor.authorKanbay, Yalcin
dc.contributor.authorAlp, Sebih
dc.contributor.authorSahin, Unal
dc.date.accessioned2020-12-19T19:41:30Z
dc.date.available2020-12-19T19:41:30Z
dc.date.issued2018
dc.identifier.issn1617-9625
dc.identifier.urihttps://doi.org/10.18332/tid/94212
dc.identifier.urihttps://hdl.handle.net/11436/1788
dc.descriptiononal, ozgur/0000-0001-6514-2120en_US
dc.descriptionWOS: 000444727000001en_US
dc.descriptionPubMed: 31516437en_US
dc.description.abstractINTRODUCTION Previous studies have shown that adherence to treatment is fundamental to success in smoking cessation. However, smoking cessation medication regimens are limited significantly by the struggle to adhere to them. This study was conducted to evaluate the factors associated with treatment adherence and quitting success in a group of patients that applied to our smoking cessation outpatient clinic (SCC). METHODS Patients that applied to SCC between April 2015 and December 2016 who were evaluated, found suitable for smoking cessation interventions and started pharmacological treatment were included in this study. Only those who could be reached by phone three months after their first application became participants. Those who had used the prescribed treatment for at least 30 days were grouped as treatment-adherent. RESULTS in total, data for 346 patients were evaluated. Mean (+/- SD) age was 44.3 +/- 13.9 years; most of them were male (63%), primary school graduated (36.1%), self-employed (43.7%), and had no comorbid diseases (71%). Bupropion was started in 52% of the patients, that rate was 35.8% for varenicline and 12.1% for a combination of the nicotine patch and gum. Mean days for treatment use was 20.9 +/- 18.5; 59% of the patients were non-adherent to their treatment and 51.7% had only one control visit number. Adverse reactions due to treatment were recorded in 25% of participants, and at their third month 37.9% of them had quit smoking. in multivariate logistic regression analysis, increase in control visit number, absence of adverse reaction, and varenicline use, were each associated with higher treatment adherence (p<0.001) and only being in the treatment-adherent group was associated with quit success (OR=3.01, 95% CI: 1.88-4.81, p=0.001). CONCLUSIONS This study showed that most patients did not use their prescribed SC treatments adequately; a main factor that affects quit success is treatment adherence. There is a need for closer monitoring and follow-up to ensure adequate use of treatment of patients.en_US
dc.language.isoengen_US
dc.publisherEuropean Publishingen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectsmokingen_US
dc.subjecttreatmenten_US
dc.subjectadherenceen_US
dc.subjectquit successen_US
dc.titleTreatment adherence and short-term outcomes of smoking cessation outpatient clinic patientsen_US
dc.typearticleen_US
dc.contributor.departmentRTEÜen_US
dc.identifier.doi10.18332/tid/94212
dc.identifier.volume16en_US
dc.ri.editoaen_US
dc.relation.journalTobacco Induced Diseasesen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US


Bu öğenin dosyaları:

DosyalarBoyutBiçimGöster

Bu öğe ile ilişkili dosya yok.

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster